Clinical Significance of Soluble Intercellular Adhesion Molecule-1 and Interleukin-6 in Patients with Extrahepatic Cholangiocarcinoma

REFERENCES

• Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet. 2005;366:1303–303e.
   Web of Science ®Google Scholar
• Katanoda K, Hori M, Matsuda T, et al. An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013. Jpn J Clin Oncol. 2015;45:390–905.
   Web of Science ®Google Scholar
• Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis. 2004;24:189–199.
   Web of Science ®Google Scholar
• Fong Y, Blumgart LH, Lin E, et al. Outcome of treatment for distal bile duct cancer. Br J Surg. 1996;83:1712–1715.
   Web of Science ®Google Scholar
• Wade TP, Prasad CN, Virgo KS, et al. Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987–1991. J Surg Oncol. 1997;64:242–245.
   Web of Science ®Google Scholar
• Esnaola NF, Meyer JE, Karachristos A, et al. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016;122:1349–1369.
   Web of Science ®Google Scholar
• Seyama Y, Makuuchi M. Current surgical treatment for bile duct cancer. World J Gastroenterol. 2007;13:1505–1515
   Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646–674.
   Web of Science ®Google Scholar
• Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425–434.
   Web of Science ®Google Scholar
• Smith MEF, Thomas JA. Cellular expression of lymphocyte function associated antigens and the intercellular adhesion molecule-1 in normal tissue. J Clin Pathol. 1990;43:893–900.
   PubMed Web of Science ®Google Scholar
• Maio M, Pinto A, Carbone A, et al. Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders. Blood. 1990;76:783–790.
   Web of Science ®Google Scholar
• Natali P, Nicotra MR, Cavaliere R, et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res. 1990;50:1271–1278.
   Web of Science ®Google Scholar
• Vánky F, Wang P, Patarroyo M, et al. Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother. 1990;31:19–27.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Staunton DE, de Fougerolles AR, et al. ICAM-1 (CD54): A counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol. 1990;111:3129–3139.
   Web of Science ®Google Scholar
• Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994;84:2068–2101.
   Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by GM-CSF plus IL-4 and downregulated by TNF-α. J Exp Med. 1994;179:1109–109M.
   Web of Science ®Google Scholar
• Shen J, Devery JM, King NJ. Adherence status regulates the primary cellular activation responses to the Flavivirus West Nile. Immunology. 1995;84:254–264.
   Web of Science ®Google Scholar
• Gho YS, Kleinman HK, Sosne G. Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res. 1999;59:5128–5132.
   Web of Science ®Google Scholar
• Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79:185–188.
   Web of Science ®Google Scholar
• Bicknell R, Harris AL. Novel growth regulatory factors and tumour angiogenesis. Eur J Cancer. 1991;27:781–785.
   Web of Science ®Google Scholar
• Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757–1763.
   Web of Science ®Google Scholar
• Laviano A, Koverech A, Mari A. Cachexia: Clinical features when inflammation drives malnutrition. Proc Nutr Soc. 2015;74:348–354.
   Web of Science ®Google Scholar
• Thompson PA, Khatami M, Baglole CJ, et al. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis. 2015;36:S232–253.
   Web of Science ®Google Scholar
• Wittekind C. Distal extrahepatic bile duct. In: Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification Of Malignant Tumours, 8th ed. John Wiley & Sons, Ltd., West Sussex, UK: Wiley Blackwell; 2017.
   Google Scholar
• Bharti R, Dey G, Mandal M. Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement. Cancer Lett. 2016;375:51–61.
   PubMed Web of Science ®Google Scholar
• Wehbe H, Henson R, Meng F, et al. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 2006;66:10517–10524.
   Web of Science ®Google Scholar
• Braconi C, Swenson E, Kogure T, et al. Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma. PLoS One. 2010;5:e15195.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Minemura M, Tsukishiro T, et al. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. Hepatology. 1995;22:525–531.
   Web of Science ®Google Scholar
• Zhu PP, Yuan SG, Liao Y, et al. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma. World J Gastroenterol. 2015;21:7254–7263.
   Web of Science ®Google Scholar
• Harning R, Mainolfi E, Bystryn JC, et al. Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res. 1991;51:5003–5005.
   Web of Science ®Google Scholar
• Grothey A, Heistermann P, Philippou S, et al. Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: Correlation with histological expression of ICAM-1 and tumour stage. Br J Cancer. 1998;77:801–807.
   Web of Science ®Google Scholar
• Zhang GJ, Adachi I. Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: Correlations with clinicopathological features and prognosis. Int J Oncol. 1999;14:71–77.
   Web of Science ®Google Scholar
• Kitagawa T, Matsumoto K, Iriyama K. Serum cell adhesion molecules in patients with colorectal cancer. Surg Today. 1998;28:262–267.
   Web of Science ®Google Scholar
• Benekli M, Güllü IH, Tekuzman G, et al. Circulating intercellular adhesion molecule-1 and E-selectin levels in gastric cancer. Br J Cancer. 1998;78:267–271.
   Web of Science ®Google Scholar
• Becker JC, Termeer C, Schmidt RE, et al. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol. 1993;151:7224–7232.
   Web of Science ®Google Scholar
• Altomonte M, Colizzi F, Esposito G, et al. Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. N Engl J Med. 1992;327:959.
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534–540.
   Web of Science ®Google Scholar
• Guthrie GJ, Charles KA, Roxburgh CS, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88:218–230.
   Web of Science ®Google Scholar
• Yazawa T, Shibata M, Gonda K, et al. Increased IL-17 production correlates with immunosuppression involving myeloid-derived suppressor cells and nutritional impairment in patients with various gastrointestinal cancers. Mol Clin Oncol. 2013;1:675–679.
   PubMedGoogle Scholar